ArticleFrontiers in neurology2025
Association between serum total bilirubin levels and 28-day all-cause mortality after intracerebral hemorrhage.
Article in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Development and Validation of an Interpretable Machine Learning-Based Clinical Prediction Model for Short-Term Mortality in Intracerebral Hemorrhage With Thrombocytopenia: A Multicenter Study.CNS neuroscience & therapeutics · 2026Article
- LDAR is superior to other albumin-derived indices in predicting 28-day ICU mortality in critically ill patients with intracerebral hemorrhage: a two-cohort study.Frontiers in nutrition · 2026Article
- Admission direct bilirubin and direct bilirubin-to-lymphocyte ratio as exploratory markers of early severity and in-hospital functional status in acute ischemic stroke.Frontiers in stroke · 2026Article
- Disruption of amino acid metabolism in acute cerebrovascular diseases: diagnostic and pathobiochemical perspectives.Frontiers in neurology · 2026Observational
- Coefficient of variation of platelet count as a prognostic Indicator for intracerebral hemorrhage: findings from a multicenter cohort.Frontiers in neurology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Intracerebral hemorrhage (ICH) is associated with high mortality and morbidity rates. Although some studies have indicated a correlation between serum bilirubin levels and ICH severity, evidence of the relationship between serum total bilirubin (TBIL) and ICH outcomes remains lacking. Methods: A total of 914 patients from the Medical Information Mart for Intensive Care IV database met the eligibility criteria and were included in the study. The patients were categorized into two groups based on whether they survived for 28 days following admission to hospital. The association between serum TBIL levels and 28-day survival in patients with ICH was investigated using Spearman's correlation analysis and restricted cubic splines. The effect of serum TBIL levels on survival time and rate in the 28-day period was analyzed using Kaplan-Meier curves and restricted mean survival times. Univariate Cox regression, least absolute shrinkage and selection operator regression, and multivariate Cox regression were used to identify risk factors associated with 28-day all-cause mortality. Finally, subgroup analysis was performed to verify the stability of the association between serum TBIL levels and 28-day all-cause mortality in patients with ICH. Results: A negative relationship was revealed between TBIL levels and survival ( Conclusion: Higher serum TBIL levels are associated with a greater risk of mortality within 28 days in patients with ICH, whereas lower serum TBIL levels are associated with prolonged survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.